Health AI Register Logo
ProductsPlatformsCompaniesNewsContact
ProductsAiMiFY

Vendor source

Reviewed 11 May 2026

Completeness Strong (64%)

AiMIFY is an image processing software that can be used for image enhancement in MRI images. It can be used to increase contrast-to-noise ratio (CNR), contrast enhancement (CEP), and lesion-to-brain ratio (LBR) of enhancing tissue in brain MRI images acquired with a gadolinium-based contrast agent. It is intended to enhance MRI images acquired using standard approved dosage per the contrast agent’s instructions for use.

No papers to support — we monitor for new evidence.

Key features

MRI image enhancement

General Information

Product name

AiMiFY

Modality

MR

Main task

Not specified

Subspeciality

Neuro

Disease targeted

Cerebritis, glioma, inflammation, lymphoma, meningioma, metastatic lesions, multiple sclerosis, neuritis, other tumor-related lesions (e.g., resection / radiation necrosis / suspected cyst / etc.), and other abnormalities.

Regulatory Information

CE Certification

Pathway:

MDR

Class:

Class IIa

Not verified by Health AI Register

FDA Certification

Pathway:

510(k) cleared

Class:

Class II

FDA Number:

K240290

View FDA record

Verified by Health AI Register

Other certifications

Not specified

Evidence & Research

No research papers or evidence on file yet.

The registry monitors publications for new evidence.

Technical Specifications

Patient population age

Adult, Elderly, Pediatric

Input

T1 weighted pre and post contrast images, gadolinium-based contrast agents, 2D and 3D sequences, axial/coronal/sagittal orientations, all major vendors, field strength: 0.3T, 1.5T, 3.0T, protocols: BRAVO, FSE, MPRAGE, T1, T1 Flair

Input format

DICOM

Output

Contrast enhanced brain MR images

Output format

DICOM

Integration

Integration CIS (Clinical Information System), Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration via AI marketplace or distribution platform

Deployment

Cloud-based, Locally on dedicated hardware, Locally virtualized (virtual machine, docker)

Trigger for analysis

Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload

Processing time

1 - 10 minutes

Population

Patiets from 7 to 86 years old. AiMIFY inherently doesn't cause harm to patients. However, gadolinium-based contrast agents are associated with contraindications, precautions, and warnings for certain subpopulations.

Market Presence

On market since

08-2024

AI Platforms

Resellers

Not specified

Countries present

Not specified

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Not specified

Based on

Not specified

Source: Vendor | First published: Jul 29, 2025 | Last updated: May 11, 2026